Biolab invests in new plant and officially launches generics unit
New industrial park in Minas Gerais receives investment of R$ 450 million
With 21 years of history dedicated to the production of reference medicines, the Biolab officially launched during the Abradilan Conexão FarmaBiolab Genéricos, a line of medicines in the sector that brings with it the challenge of reaching the market with a portfolio of exclusive and semi-exclusive products. Biolab's entry into generics is the result of the purchase of Actavis Brasil, a company that belonged to the Israeli company Teva, the world's largest generic manufacturer. "Today, we have approximately 35 molecules and, by the middle of the year, we will have 60 molecules. We will maintain our prescription line and continue, in parallel, with the generic line," says Biolab's CEO, Cleiton de Castro Marques. Today, in the prescription area, the pharmacist's specialty is in cardiology. As a result, generics in cardiology tend to be a highlight for the company, in addition to the Central Nervous System (CNS) segment, which Actavis specializes in.
In addition to this investment, Biolab announced the opening of a new plant in Minas Gerais, with an investment of R$ 450 million, which will be responsible for both branded and generic drugs, a category that the executive reinforces is a reality in the country. "Generics reach a different world from the prescription drugs market, which today is very much related to the big chains. So it's an opportunity for us to enter new markets and reach new audiences. We want to bring more capillarity to our products," says Marques, adding that the company took part in the fair for the first time precisely to achieve this goal. "The pharma channel has been very receptive, precisely because of the serious image the company has already achieved - especially with doctors - with prescription drugs. We have ambitious plans for this market," he concluded.